BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 214
- Registration Number
- NCT00095173
- Locations
- 🇨🇭
Local Institution, Lausanne, Switzerland
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo (PLA) + MTX, DBDrug: PLA + MTX switched to ABA+ MTX, DBDrug: ABA, open-label (OL)
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 431
- Registration Number
- NCT00095147
- Locations
- 🇨🇭
Local Institution, St. Gallen, Switzerland
Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4128
- Registration Number
- NCT00095238
- Locations
- 🇬🇧
Local Institution, Londonderry, United Kingdom
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT00094991
- Locations
- 🇮🇹
Local Institution, Pisa, Italy
Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2010-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1752
- Registration Number
- NCT00095030
- Locations
- 🇹🇭
Local Institution, Bangkok, Thailand
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Phase 3
Completed
- Conditions
- MelanomaMetastases
- Interventions
- Biological: MDX-1379 (gp100) Melanoma Peptide VaccineDrug: MDX-010 (anti-CTLA4) monoclonal antibody
- First Posted Date
- 2004-10-22
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1783
- Registration Number
- NCT00094653
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients
Phase 4
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: Atazanavir/ Stavidine / LamivudineDrug: Atazanavir-Ritonavir/ Stavidine / Lamivudine
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2010-03-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00084253
- Locations
- 🇺🇸
Various locations within the US, Call for Information, New Jersey, United States
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Phase 2
Completed
- Conditions
- Intraocular MelanomaMelanoma (Skin)
- Interventions
- Biological: ipilimumabBiological: Tyrosinase/gp100/MART-1 Peptides
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 77
- Registration Number
- NCT00084656
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States
Study of MDX-010 in Stage IV Breast Cancer
Phase 2
Completed
- Conditions
- Breast CancerAdenocarcinoma
- First Posted Date
- 2004-05-20
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT00083278
- Locations
- 🇺🇸
LaGrange, LaGrange, Kentucky, United States
🇺🇸Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸Medical Arts Building, Jeffersonville, Indiana, United States
Effectiveness of KOS-862 in the Treatment of Lung Cancer
Phase 2
Terminated
- Conditions
- Lung Cancer
- First Posted Date
- 2004-04-07
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT00080509
© Copyright 2025. All Rights Reserved by MedPath